Understanding HIV latency: The road to an HIV cure

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 407-421

  Dahabieh, Matthew S ^a   Battivelli, Emilie ^a   Verdin, Eric ^a  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

Author keywords

HIV 1; lymphocyte; quiescence; Tat; transcription

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYTOKINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; ERADICATION THERAPY; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL SYNAPSE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; SURVIVAL; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS LATENCY; GENE EXPRESSION REGULATION; GENETICS; HIV INFECTIONS; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; VIRUS LATENCY;

EID: 84921324809     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-092112-152941     Document Type: Article

References (102)

1. Lohse N, Hansen AB. 2007. Survival of persons with and without HIV infection in Denmark. Ann. Intern. Med. 146(2): 87-95
2. Torres RA, Lewis W. 2013. Aging and HIV AIDS: pathogenetic role of therapeutic side effects. Lab. Invest. 94(2):120-28
3. Cory TJ, Schacker TW, Stevenson M, et al. 2013. Overcoming pharmacologic sanctuaries. Curr. Opin. HIV AIDS 8(3):190-95
4. Deeks SG. 2012. HIV: shock and kill. Nature 487(7408):439-40
5. Donahue DA, Wainberg MA. 2013. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology 10:11
6. Ruelas DS, GreeneWC. 2013. An integrated overview of HIV-1 latency. Cell 155(3):519-29
7. Van Lint C, Bouchat S, Marcello A. 2013. HIV-1 transcription and latency: an update. Retrovirology 10:67
8. Sherrill-Mix S, Lewinski MK, Famiglietti M, et al. 2013. HIV latency and integration site placement in five cell-based models. Retrovirology 10:90
9. Spina CA, Anderson J, Archin NM, et al. 2013. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 9(12):e1003834
10. Ho Y-C, Shan L, Hosmane NN, et al. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155(3):540-51
11. Hakre S, Chavez L, Shirakawa K, et al. 2012. HIV latency: experimental systems and molecular models. FEMS Microbiol. Rev. 36:706-16
12. Wang GP, Ciuffi A, Leipzig J, et al. 2007. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 17(8):1186-94
13. Brady T, Agosto LM, Malani N, et al. 2009. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 23(12):1461-71
14. Ciuffi A, Llano M, Poeschla E, et al. 2005. A role for LEDGF p75 in targeting HIV DNA integration. Nat. Med. 11(12):1287-89
15. Schrijvers R, De Rijck J, Demeulemeester J, et al. 2012. LEDGF p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog. 8(3):e1002558
16. Jordan A, Defechereux P, Verdin E. 2001. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 20(7):1726-38
17. Jordan A, Bisgrove D, Verdin E. 2003.HIVreproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22(8):1868-77
18. Lewinski MK, BisgroveD, Shinn P, et al. 2005. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 79(11):6610-19
19. Singh A, Razooky B, Cox CD, et al. 2010. Transcriptional bursting from the HIV-1 promoter is a significant source of stochastic noise in HIV-1 gene expression. Biophys. J. 98(8):L32-L34
20. Dar RD, Razooky BS, Singh A, et al. 2012. Transcriptional burst frequency and burst size are equally modulated across the human genome. Proc. Natl. Acad. Sci. USA 109(43):17454-59
21. Han Y, Lin YB, An W, et al. 2008. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 4(2):134-46
22. Shan L, Yang HC, Rabi SA, et al. 2011. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J. Virol. 85(11):5384-93
23. Lenasi T, Contreras X, Peterlin BM. 2008. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 4(2):123-33
24. Gallastegui E, Millan-Zambrano G, Terme JM, et al. 2011. Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J. Virol. 85(7):3187-202
25. Han Y, Lassen K, Monie D, et al. 2004. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78(12):6122-33
26. Dahabieh MS, OomsM, Brumme C, et al. 2014. Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NF?B. Retrovirology 11(1):1-17
27. Miller-Jensen K, Dey SS, Pham N, et al. 2012. Chromatin accessibility at the HIV LTR promoter sets a threshold for NF-?B mediated viral gene expression. Integr. Biol. Quant. Biosci. Nano Macro 4(6):661-71
28. Politz JCR, Scalzo D, Groudine M. 2013. Something silent this way forms: the functional organization of the repressive nuclear compartment. Annu. Rev. Cell Dev. Biol. 29(1):241-70
29. Luperchio TR, Wong X, Reddy KL. 2014. ScienceDirectGenome regulation at the peripheral zone: lamina associated domains in development and disease. Curr. Opin. Genet. Dev. 25:50-61
30. Morimoto M, Boerkoel C. 2013. The role of nuclear bodies in gene expression and disease. Biology 2(3):976-1033
31. Albanese A, Arosio D, Terreni M, et al. 2008. HIV-1 pre-integration complexes selectively target decondensed chromatin in the nuclear periphery. PLoS ONE 3(6):e2413
32. Dieudonne M, Maiuri P, Biancotto C, et al. 2009. Transcriptional competence of the integrated HIV-1 provirus at the nuclear periphery. EMBO J. 28(15):2231-43
33. Lusic M, Marini B, AliH, et al. 2013. Proximity to PMLnuclear bodies regulates HIV-1 latency inCD4+ T cells. Cell Host Microbe 13(6):665-77
34. Marcello A, Ferrari A, Pellegrini V, et al. 2003. Recruitment of human cyclin T1 to nuclear bodies through direct interaction with the PML protein. EMBO J. 22:2156-66
35. Weinberger LS, Burnett JC, Toettcher JE, et al. 2005. Stochastic gene expression in a lentiviral positivefeedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122(2):169-82
36. Kutsch O, Benveniste ENN, Shaw GMM, et al. 2002. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J. Virol. 76(17):8776-86
37. Sahu GK, Lee K, Ji J, et al. 2006. A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+ T-lymphocytes. Virology 355(2):127-37
38. Tyagi M, Pearson RJ, Karn J. 2010. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84(13):6425-37
39. Marini A, Harper JM, Romerio F. 2008. An in vitro system to model the establishment and reactivation of HIV-1 latency. J. Immunol. 181(11):7713-20
40. Bosque A, Planelles V. 2009. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113(1):58-65
41. Yang H-CC, Xing S, Shan L, et al. 2009. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119(11):3473-86
42. Lassen KG, Hebbeler AM, Bhattacharyya D, et al. 2012. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS ONE 7(1):e30176
43. van der Sluis RM, van Montfort T, Pollakis G, et al. 2013. Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLoS Pathog. 9(3):e1003259
44. van der Sluis RM, Derking R, Breidel S, et al. 2014. The interplay between the viral Tat protein and the c-Jun transcription factor in controlling the activity of the LTR promoter in the different human immunodeficiency virus type I subtypes. J. Gen. Virol. 5(4):968-79
45. Dahabieh MS, Ooms M, Simon V, et al. 2013. A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection. J. Virol. 87(8):4716-27
46. Calvanese V, Chavez L, Laurent T, et al. 2013. Dual-color HIV reporters trace a population of latently infected cells and enable their purification. Virology 446(1-2):283-92
47. Farber DL, YudaninNA, Restifo NP. 2014. Human memory T cells: generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 14(1):24-35
48. Chomont N, El-Far M, Ancuta P, et al. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15(8):893-900
49. Gattinoni L, Lugli E, Ji Y, et al. 2011. A human memory T cell subset with stem cell-like properties. Nat. Med. 17(10):1290-97
50. Buzon MJ, Sun H, Li C, et al. 2014. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat. Med. 20(2):139-42
51. Delon J, Bercovici N, Raposo G, et al. 1998. Antigen-dependent and-independent Ca2+ responses triggered in T cells by dendritic cells compared with B cells. J. Exp. Med. 188(8):1473-84
52. Revy P, Sospedra M, Barbour B, et al. 2001. Functional antigen-independent synapses formed between T cells and dendritic cells. Nat. Immunol. 2(10):925-31
53. Geijtenbeek TB, KwonDS, Torensma R, et al. 2000. DC-SIGN, a dendritic cell-specificHIV-1-binding protein that enhances trans-infection of T cells. Cell 100(5):587-97
54. Yu HJ, ReuterMA, McDonald D. 2008. HIV traffics through a specialized, surface-Accessible intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS Pathog. 4(8):e1000134
55. StadeliKM, Richman DD. 2012. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir. Ther. 18(1):115-23
56. Evans VA, Kumar N, Filali A, et al. 2013. Myeloid dendritic cells induce HIV-1 latency in nonproliferating CD4+ T cells. PLoS Pathog. 9(12):e1003799
57. Rodriguez-PlataMT, Puigdomenech I, Izquierdo-Useros N, et al. 2013. The infectious synapse formed between mature dendritic cells and CD4+ T cells is independent of the presence of the HIV-1 envelope glycoprotein. Retrovirology 10:42
58. Kwon DS, Angin M, Hongo T, et al. 2012. CD4+ CD25+ regulatory T cells impair HIV-1-specific CD4 T cell responses by upregulating interleukin-10 production in monocytes. J. Virol. 86(12):6586-94
59. Said EA, Dupuy FP, Trautmann L, et al. 2010. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat. Med. 16(4):452-59
60. Elrefaei M, Burke CM, Baker CA, et al. 2010. HIV-specific TGF-beta-positive CD4+ T cells do not express regulatory surface markers and are regulated by CTLA-4. AIDS Res. Hum. Retrovir. 26(3):329-37
61. Li MO, Sanjabi S, Flavell RA. 2006. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and-independent mechanisms. Immunity 25(3):455-71
62. Baldauf HM, Pan X, Erikson E, et al. 2012. SAMHD1 restricts HIV-1 infection in resting CD4+ T cells. Nat. Med. 18(11):1682-87
63. Cameron PU, Saleh S, Sallmann G, et al. 2010. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc. Natl. Acad. Sci. USA 107(39):16934-39
64. Saleh S, Solomon A, Wightman F, et al. 2007. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110(13):4161-64
65. Ducrey-Rundquist O, Guyader M, Trono D. 2002. Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. J. Virol. 76(18):9103-11
66. UnutmazD, KewalramaniVN, Marmon S, et al. 1999. Cytokine signals are sufficient forHIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189(11):1735-46
67. Chun TW, Engel D, Mizell SB, et al. 1998. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. 188(1):83-91
68. Iannello A, Boulassel MR, Samarani S, et al. 2010. HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication. J. Infect. Dis. 201(4):608-17
69. Riou C, Yassine-Diab B, Van Grevenynghe J, et al. 2007. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J. Exp.Med. 204(1):79-91
70. Chetoui N, Boisvert M, Gendron S, et al. 2010. Interleukin-7 promotes the survival of human CD4+ effector memoryTcells by up-regulatingBcl-2 proteins and activating the JAKSTATsignalling pathway. Immunology 130(3):418-26
71. Larsson M, Shankar EM, Che KF, et al. 2013. Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology 10:31
72. Day CL, Kaufmann DE, Kiepiela P, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109):350-54
73. Hatano H. 2013. Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr. Opin. HIV AIDS 8(3):211-16
74. DaFonseca S, Chomont N, El Far M, et al. 2010. Purging the HIV-1 reservoir through the disruption of the PD-1 pathway. J. Int. AIDS Soc. 13(Suppl. 3):O15
75. Parry RV, Chemnitz JM, Frauwirth KA, et al. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25(21):9543-53
76. Kaufmann DE, Walker BD. 2009. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J. Immunol. 182(10):5891-97
77. Leng Q, Bentwich Z, Magen E, et al. 2002. CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention. AIDS 16(4):519-29
78. Wherry EJ, Ha SJ, Kaech SM, et al. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27(4):670-84
79. Williams KL, Nanda I, Lyons GE, et al. 2001. Characterization of murine BATF: a negative regulator of activator protein-1 activity in the thymus. Eur. J. Immunol. 31(5):1620-27
80. Duverger A, Wolschendorf F, Zhang M, et al. 2013. An AP-1 binding site in the enhancer core element of theHIV-1 promoter controls the ability ofHIV-1 to establish latent infection. J. Virol. 87(4):2264-77
81. Juffroy O, Bugault F, Lambotte O, et al. 2010. Dual mechanism of impairment of interleukin-7 (IL-7) responses in human immunodeficiency virus infection: decreased IL-7 binding and abnormal activation of the JAK STAT5 pathway. J. Virol. 84(1):96-108
82. Tzachanis D, Lafuente EM, Li L, et al. 2004. Intrinsic and extrinsic regulation of T lymphocyte quiescence. Leuk. Lymphoma 45(10):1959-67
83. Van Der Heide LP, Hoekman MF, Smidt MP. 2004. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem. J. 380(Pt. 2):297-309
84. Swiggard WJ, Baytop C, Yu JJ, et al. 2005. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J. Virol. 79(22):14179-88
85. Shalek AK, Satija R, Adiconis X, et al. 2013. Single-cell transcriptomics reveals bimodality inexpression and splicing in immune cells. Nature 498(7453):236-40
86. Feinerman O, Jentsch G, Tkach KE, et al. 2010. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol. Syst. Biol. 6:1-16
87. Van Lint C, Emiliani S, Ott M, et al. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15(5):1112-20
88. Siliciano JD, Lai J, Callender M, et al. 2007. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195:833-36
89. Sagot-Lerolle N, Lamine A, Chaix ML, et al. 2008. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 22:1125-29
90. Archin NM, Eron JJ, Palmer S, et al. 2008. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22:1131-35
91. Archin NM, Liberty AL, Kashuba AD, et al. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487(7408):482-85
92. Xing S, Siliciano RF. 2013. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov. Today 18(11-12):541-51
93. Bullen CK, Laird GM, Durand CM, et al. 2014. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat. Med. 20(4):425-29
94. Cillo AR, Sobolewski MD, Bosch RJ, et al. 2014. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 111(19):7078-83
95. Shan L, DengK, ShroffNS, et al. 2012. Stimulation ofHIV-1-specific cytolyticTlymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36(3):491-501
96. Jern P, Coffin JM. 2008. Effects of retroviruses on host genome function. Annu. Rev. Genet. 42(1):709-32
97. Mancebo HS, Lee G, Flygare J, et al. 1997. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11(20):2633-44
98. Biglione S, Byers SA, Price JP, et al. 2007. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 4:47
99. Duverger A, Wolschendorf F, Anderson JC, et al. 2013. Kinase control of latentHIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J. Virol. 88(1):364-76
100. Anderson I, Low JS, Weston S, et al. 2014. Heat shock protein 90 controls HIV-1 reactivation from latency. Proc. Natl. Acad. Sci. USA 111(15):1528-37
101. Hu W, Kaminski R, Yang F, et al. 2014. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc. Natl. Acad. Sci. USA 111(31):11461-66
102. Ebina H, Misawa N, Kanemura Y, et al. 2013. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep. 3:2510